Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M304153200 on July 7, 2003

J. Biol. Chem., Vol. 278, Issue 38, 36091-36098, September 19, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/38/36091    most recent
M304153200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaneko, E.
Right arrow Articles by Makishima, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaneko, E.
Right arrow Articles by Makishima, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Induction of Intestinal ATP-binding Cassette Transporters by a Phytosterol-derived Liver X Receptor Agonist*

Emi Kaneko {ddagger}, Morihiro Matsuda §, Yukio Yamada § , Yoji Tachibana ||, Iichiro Shimomura {ddagger} § ** {ddagger}{ddagger} and Makoto Makishima {ddagger} § ** {ddagger}{ddagger}

From the {ddagger}Graduate School of Medicine and §Graduate School of Frontier Biosciences, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan and ||Pharmaceutical Research Center of Nisshin Flour Milling Co., 5-3-1 Tsurugaoka, Ooi-machi, Saitama 356-8511, Japan

Received for publication, April 21, 2003 , and in revised form, June 23, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The nuclear receptors liver X receptor (LXR) {alpha} and LXR{beta} serve as oxysterol receptors and regulate the expression of genes involved in lipid metabolism. LXR activation induces the expression of ATP-binding cassette (ABC) transporters, such as ABCG5 and ABCG8, which inhibit intestinal absorption of cholesterol and phytosterols. Although several synthetic LXR agonists have been generated, these compounds have limited clinical application, because they cause hypertriglycemia by inducing the expression of lipogenic genes in the liver. We synthesized derivatives of phytosterols and found some of them to act as LXR agonists. Among them, YT-32 [(22E)-ergost-22-ene-1{alpha},3{beta}-diol], which is related to ergosterol and brassicasterol, is the most potent LXR agonist. YT-32 directly bound to LXR{alpha} and LXR{beta} and induced the interaction of LXR{alpha} with cofactors, such as steroid receptor coactivator-1, as effectively as the natural ligands, 22(R)-hydroxycholesterol and 24(S),25-epoxycholesterol. Although the nonsteroidal synthetic LXR agonist T09013 [GenBank] 17 induced the expression of intestinal ABC transporters and liver lipogenic genes, oral administration of YT-32 selectively activated intestinal ABC transporters in mice. Unlike T09013 [GenBank] 17 treatment, YT-32 inhibited intestinal cholesterol absorption without increasing plasma triglyceride levels. The phytosterol-derived LXR agonist YT-32 might selectively modulate intestinal cholesterol metabolism.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Cholesterol is an essential compound in all eukaryotic organisms. It serves as a precursor of steroids such as corticosteroids, sex hormones, vitamin D, and bile acids and serves as an essential structural component of cell membranes (1). Cholesterol homeostasis is maintained by de novo synthesis, absorption from diet, catabolism to bile acids, and excretion into bile. Dysregulation of this mechanism leads to hypercholesterolemia and atherosclerosis, resulting in life-threatening coronary and cerebrovascular disease (2).

The liver X receptors (LXRs)1 are oxysterol-activated nuclear receptor family transcription factors that regulate the expression of genes involved in cholesterol metabolism (3). LXR{alpha} (NR1H3) is mainly localized in liver, adipose tissue, intestine, kidney, and macrophages, whereas LXR{beta} (NR1H2) is ubiquitously expressed. In the rodent liver, LXR{alpha} induces transcription of cholesterol 7{alpha}-hydroxylase (CYP7A), the rate-limiting enzyme in the bile acid synthesis. Treatment with LXR agonists prevents the overaccumulation of sterols in the intestine and macrophages by the induction of ATP-binding cassette (ABC) transporters involved in sterol efflux along with acceptor proteins such as apoprotein E (4). In macrophages, activation of LXRs stimulates transcription of the ABC transporters, ABCA1 and ABCG1. Synthetic LXR ligand administration reduced the development of atherosclerosis in mice deficient in low density lipoprotein receptor or apoprotein E (5). Mice with macrophages lacking both LXR{alpha} and LXR{beta} developed more atherosclerotic lesions than mice with wild-type macrophages (6). In the small intestine, ABCA1, ABCG5, and ABCG8 are induced by LXR activation, which results in reduced sterol absorption (7, 8). These studies suggest that LXRs play an important role in the regulation of cholesterol homeostasis.

In addition to their role in maintaining cholesterol homeostasis, LXRs also regulate fatty acid metabolism. Administration of synthetic LXR agonists to mice induced expression of fatty acid biosynthetic genes, such as acetyl CoA carboxylase, fatty acid synthase (FAS), and stearyl CoA desaturase-1, in liver and increased plasma triglyceride and phospholipid levels (9). LXRs regulate expression of sterol regulatory element-binding protein-1c (SREBP-1c), a transcription factor that regulates the expression of genes involved in fatty acid biosynthesis (10). LXRs also act on the promoters of FAS and angiopoietin-like protein 3, a liver-specific secretory protein, which inactivates lipoprotein lipase and increases plasma triglyceride levels (11–14). Because LXRs have both antiatherogenic and lipogenic activities, the development of LXR agonists that could regulate cholesterol metabolism without adverse hypertriglycemia-inducing effects is of great pharmacological interest.

Phytosterols are naturally occurring sterols and are the plant equivalents of mammalian cholesterol. The effects of phytosterols in reducing blood cholesterol have been demonstrated for several decades, although the precise mechanism has not been elucidated (15). Recently, ABCG5 and ABCG8 have been proposed to function as transporters for cholesterol and phytosterols (16–18). The findings that the expression of ABCG5 and ABCG8 is induced by LXR activation (8) and that the treatment of intestinal cells with phytosterols increases the expression of LXR target genes (19) suggest that phytosterols, or their metabolites, act as LXR ligands and influence cholesterol metabolism. At present, no phytosterol has been identified as a LXR ligand. In this work, we examined the effects of several phytosterols and their derivatives on the activity of LXRs and found that a compound related to ergosterol and brassicasterol is a potent agonist for LXRs.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Chemical Compounds—T0901317 was purchased from Cayman Chemical (Ann Arbor, MI), 22(R)-Hydroxycholesterol, 24(S),25-epoxycholsterol, fucosterol, and fucostanol were from Steraloids (Newport, RI), ergosterol was from Nacalai (Kyoto, Japan), and brassicasterol, campesterol, {beta}-sitosterol, and stigmasterol were from Wako (Osaka, Japan). YT compounds were synthesized as reported previously (20).2

Plasmids—Fragments of hLXR{alpha} (GenBankTM accession number NM_005693 [GenBank] ), hLXR{beta} (accession number NM_007121 [GenBank] ), mLXR{alpha} (accession number NM_013839 [GenBank] ), and mLXR{beta} (accession number U09419 [GenBank] ) were inserted into pCMX vector to make pCMX-hLXR{alpha}, pCMX-hLXR{beta}, pCMX-mLXR{alpha}, and pCMX-mLXR{beta}, respectively (21). The ligand-binding domains of hLXR{alpha}, hLXR{beta}, and h retinoid X receptor (RXR){alpha} were inserted into pCMX-GAL4 vector to make pCMX-GAL4-hLXR{alpha}, pCMX-GAL4-hLXR{beta}, and pCMX-GAL4-hRXR{alpha}, respectively (22), and full-length fragment of hLXR{alpha} was inserted into pCMX-VP16 vector to make pCMX-VP16-hLXR{alpha} (23). The amino acid 1–436 fragment of hLXR{alpha} was inserted into pCMX to generate pCMX-hLXR{alpha}-dAF-2. Nuclear hormone receptor-interacting domains of steroid receptor coactivator-1 (SRC-1) (amino acids 595–771; GenBankTM accession number U90661 [GenBank] ), ACTR (601–780; accession number AF036892 [GenBank] ), DRIP205 (578–728; accession number Y13467 [GenBank] ), and RIP140 (480–600; accession number X84373 [GenBank] ) were inserted into pCMX-GAL4 vector for pCMX-GAL4-SRC-1, pCMX-GAL4-ACTR, pCMX-GAL4-DRIP205, and pCMX-GAL4-RIP140, respectively (24). LXR-responsive rCYP7A-DR-4x3-tk-LUC and GAL4-responsive MH100(UAS)x4-tk-LUC reporters were utilized to evaluate the activities of LXRs and GAL4-chimera receptors (22, 25). All plasmids were sequenced prior to use to verify DNA sequence fidelity.

Cell Culture and Cotransfection Assay—Human embryonic kidney 293 cells were cultured in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum and antibiotic-antimycotic (Nacalai) at 37 °C in a humidified atmosphere of 5% CO2 in air. Transfections were performed by the calcium phosphate coprecipitation assay as described previously (23, 26). Eight h after transfection, test compounds were added. Cells were harvested after 16 to 24 h for luciferase and {beta}-galactosidase activity using a luminometer (Molecular Devices, Sunnyvale, CA). DNA cotransfection experiments involved utilization of 50 ng of reporter plasmid, 20 ng of pCMX-{beta}-galactosidase, 15 ng of each receptor and/or cofactor expression plasmid, and pGEM carrier DNA to give 150 ng of DNA total per well of a 96-well plate. Luciferase data were normalized to an internal {beta}-galactosidase control and represent the mean (±S.D.) of triplicate assays.

Glutathione S-transferase (GST) Pull-down Assays—Nuclear receptor interaction domain of SRC-1 (amino acids 601–771) was cloned into the GST fusion vector pGEX-4T1 (Amersham Biosciences). GST-SRC-1 fusion protein was expressed in BL21 DE3 cells (Promega, Madison, WI). 35S-Labeled LXRs were generated using the TNT Quick Coupled Transcription/Translation System (Promega). GST pull-down assays were performed as reported previously (26, 27). Approximately 1 µg of GST-SRC-1 was bound in glutathione-Sepharose beads (Amersham Biosciences) and equilibrated in binding buffer (20 mM Tris-HCl, pH 8, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40). Bound GST proteins were then incubated with labeled LXR and test ligand for 1.5 h at 4 °C. After binding, beads were washed three times with washing buffer (20 mM Hepes, pH 7.7, 50 mM KCl, 20% glycerol, 0.1% Nonidet P-40), resuspended in SDS-PAGE sample buffer, and loaded onto a 10% SDS-polyacrylamide gel. After electrophoresis, bound proteins were visualized by autoradiography and quantified utilizing BAS2500 system (Fujifilm, Tokyo, Japan).

Animal Studies—C57BL/6J mice were obtained from Charles River (Yokohama, Japan) and housed in a room under controlled temperature (23 ± 1 °C) and humidity (45–65%) and had free access to water and chow (Oriental Yeast, Tokyo). Experiments were conducted when the mice (males) were between 8 and 9 weeks of age. Mice were treated orally with YT-32, YT-33, or T09013 [GenBank] 17 in a polyethylene glycol/Tween 80 (4/1) formulation or vehicle alone. Mice were analyzed 12 h after treatment under non-fasting conditions. Plasma triglyceride levels were determined with Triglycerides E-test Wako (Wako). To evaluate intestinal cholesterol absorption, mice were administered 20 µCi of [1{alpha},2{alpha}(n)-3H] cholesterol (Amersham Biosciences) suspended in 150 µl of oil via gavage 12 h after treatment with YT-32, YT-33, or T09013 [GenBank] 17, and radioactivities in 10 µl of plasma were measured with a liquid scintillation spectrometer. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Osaka University.

Quantitative Reverse Transcription-PCR—Total RNAs from liver or intestinal mucosa were prepared with an RNA STAT-60 kit (Tel-Test, Friendswood, TX). The cDNA was synthesized using TaqMan reverse transcription kits (PerkinElmer Life Sciences). Real time PCR was performed on a LightCycler using the FastStart DNA Master SYBR Green I (Roche Diagnostics) using the instructions provided by the manufacturer. Primers were as follows: mouse ABCA1, 5'-ATT GCC AGA CGG AGC CG-3' and 5'-TGC CAA AGG GTG GCA CA-3'; ABCG5, 5'-TCA GGA CCC CAA GGT CAT GAT-3' and 5'-AGG CTG GTG GAT GGT GAC AAT-3'; ABCG8, 5'-GAC AGC TTC ACA GCC CAC AA-3' and 5'-GCC TGA AGA TGT CAG AGC GA-3'; SREBP-1c, 5'-GGA CCA CGG AGC CAT GG-3' and 5'-GGA AGT CAC TGT CTT GGT TGT TGA-3'; LXR{alpha}, 5'-ATG CGG CGG AAA TGC CAG GA-3' and 5'-TAC ACT GTT GCT GGG CAG CC-3'; LXR{beta}, 5'-CCG AAG ATG CTG GGC CAT GA-3' and 5'-CAT GCC AGC CTC CTT GCA CT-3'; FAS, 5'-GCT TTG CTG CCG TGT CCT TCT-3' and 5'-TCT AGC CCT CCC GTA CAC TCA-3'; 18 S ribosomal RNA, 5'-CGG CTA CCA CAT CCA AGG AA-3' and 5'-GCT GGA ATT ACC GCG GCT-3'. The RNA values were normalized to the amount of 18 S ribosomal RNA and are represented in arbitrary units.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Identification of Phytosterol Derivatives as LXR Agonists— The effects of phytosterols including ergosterol, brassicasterol, campesterol, {beta}-sitosterol, stigmasterol, and fucosterol on LXR{alpha} were examined by using the GAL4-chimeric receptor assay. The ligand-binding domain of hLXR{alpha} was fused to the DNA-binding domain of the yeast transcriptional factor GAL4 (28). The GAL4-hLXR{alpha} expression plasmid was cotransfected with a GAL4-responsive luciferase reporter into human embryonic kidney 293 cells. Because this reporter is activated only by the GAL4-chimera receptor, the potentially confounding effects of endogenous receptors are eliminated. As reported previously (9, 29), the oxysterol 24(S),25-epoxycholesterol and the synthetic ligand T09013 [GenBank] 17 induced the activation of LXR{alpha} (Fig. 1). None of the naturally occurring phytosterols were able to activate LXR{alpha}. Next, we tested a panel of synthetic phytosterol derivatives (YT compounds) (Fig. 1). Ergosterol derivatives (YT-6 and YT-32), a campesterol derivative (YT-4), a stigmasterol derivative (YT-17), and a poriferasterol derivative (YT-34) induced LXR{alpha} activation. Among the test compounds, YT-32 [(22E)-ergost-22-ene-1{alpha},3{beta}-diol] was the most efficacious LXR{alpha} agonist at 10 µM. Interestingly, at this concentration, YT-32 activated GAL4-hLXR{alpha} more effectively than an endogenous LXR ligand, 24(S),25-epoxycholsterol. Therefore, YT-32 is identified as a potent sterol agonist for GAL4-hLXR{alpha}.



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 1.
Phytosterol derivatives activate LXR{alpha}. Human embryonic kidney 293 cells were cotransfected with GAL4-hLXR{alpha} expression vector in combination with GAL4-responsive MH100(UAS)x4-tk-LUC reporter. Cells were then incubated with vehicle control (EtOH), phytosterols or their derivatives (10 µM) and assayed for luciferase activity. Luciferase activity of the reporter is expressed as -fold induction of compound treatment relative to vehicle control. The values represent means ± S.D.

 

YT-32 Is a Potent Agonist for LXRs—The effects of YT-32 on hLXR{beta} and the LXR heterodimerization partner hRXR{alpha} were examined. YT-32, but not ergosterol, activated GAL4-hLXR{beta}, whereas both compounds had no effect on RXR{alpha} (Fig. 2A). Although RXR ligands have been reported to induce the activation of LXR/RXR heterodimers (22), the data indicate that YT-32 activates LXR{alpha}/RXR and LXR{beta}/RXR heterodimers by acting on LXRs. YT-32 did not activate PPAR{alpha}, PPAR{delta}, PPAR{gamma}, FXR, VDR, PXR, or CAR (data not shown). Because some nuclear receptors are known to exhibit species-specific ligand selectivity (30), we next examined the effects of YT-32 on mouse LXRs by cotransfecting full-length mouse LXR{alpha} or LXR{beta} vectors and a luciferase reporter containing the DR-4 element (LXRE) of the rat CYP7A promoter (25). YT-32 activated mLXR{alpha} and mLXR{beta} to levels equivalent to or greater than 22(R)-hydroxycholesterol, another physiological LXR agonist (31), whereas ergosterol had no activity on mouse LXRs (Fig. 2B).



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 2.
YT-32 is a potent agonist for LXRs. A, effects of YT-32 on hLXR{beta} and hRXR{alpha}. Cells were cotransfected with GAL4-hLXR{beta} or GAL4-hRXRa vector in combination with MH100(UAS)x4-tk-LUC reporter and treated with vehicle control (EtOH), ergosterol, YT-32, or 22(R)-hydroxycholesterol (22(R)-HC) at 10 µM. B, effect of YT-32 on mLXR{alpha} and mLXR{beta}. Cells were cotransfected with CMX control vector, CMX-mLXR{alpha}, or CMX-mLXR{beta} in combination with rCYP7A-DR-4x3-tk-LUC reporter. C, AF-2-dependent activation of LXR{alpha} by YT-32. Cells were cotransfected with CMX control vector, CMX-hLXR{alpha}, or CMX-hLXR{alpha}-dAF-2 and rCYP7A-DR-4x3-tk-LUC and treated with EtOH control or 10 µM YT-32. D, association of LXR{alpha} with cofactors induced by YT-32. Cells were cotransfected with GAL4 control vector or GAL4-chimera vector for SRC-1, ACTR, DRIP205, or RIP140, in combination with VP16 control or VP16-hLXRa vector and MH100(UAS)x4-tk-LUC reporter and treated with EtOH control, 10 µM YT-32, 22(R)-hydroxycholesterol, 24(S),25-epoxycholesterol (24(S),25-EC), or 100 nM T09013 [GenBank] 17. The values represent means ± S.D.

 

Upon ligand bindings, nuclear receptors undergo a conformational change that induces C-terminal activation function-2 (AF-2)-dependent recruitment of coactivators such as SRC-1 (32). We examined the effect of YT-32 on an LXR{alpha} AF-2 deletion mutant. YT-32-dependent activation of LXR{alpha} was completely abolished by truncation of the AF-2 domain (Fig. 2C). To assay ligand-dependent interactions of LXR{alpha} with cofactors, the receptor-interacting domains of SRC-1, ACTR, DRIP205, and RIP140 were fused to the GAL4 DNA-binding domain (24). Cotransfection of GAL4 cofactors with LXR{alpha} fused to the transactivation domain of herpesvirus VP16 protein allowed for detection of ligand-dependent cofactor recruitment (28). YT-32, 22(R)-hydroxycholesterol, 24(S),25-epoxycholesterol, and T09013 [GenBank] 17 induced LXR{alpha}-SRC-1 interaction (Fig. 2D). YT-32 and the other agonists also induced the association of LXR{alpha} with ACTR, DRIP205, and RIP140. Interestingly, YT-32 stimulated interaction of LXR{alpha} with ACTR and DRIP205 more efficiently than the oxysterol agonists 22(R)-hydroxycholesterol and 24(S),25-epoxycholesterol at 10 µM.

To determine whether YT-32 binds directly to LXR{alpha}, GST pull-down analysis was performed. We generated a fusion protein of GST and the nuclear receptor-interacting domain of SRC-1 and evaluated the ligand-dependent interaction between GST-SRC-1 and isotope-labeled hLXR{alpha}. Although LXR{alpha} did not bind to SRC-1 in the absence of ligand, YT-32 and T09013 [GenBank] 17 induced the association of LXR{alpha} with SRC-1 in a concentration-dependent manner (Fig. 3). These interactions were not observed when the AF-2 domain of LXR{alpha} was deleted (Fig. 3). YT-32 also induced the interaction of hLXR{beta} with SRC-1 as effectively as T09013 [GenBank] 17 (Fig. 3). The data demonstrate that YT-32 activates LXRs by direct binding.



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 3.
YT-32 induces interaction between LXRs and SRC-1 in vitro. GST pull-down assays were performed to demonstrate in vitro binding of YT-32 to LXR{alpha} and LXR{beta}. Addition of YT-32 or T09013 [GenBank] 17 induced the interaction of GST-SRC-1 with 35S-labeled LXR{alpha} in a concentration dependent manner (upper panel) but not with 35S-labeled LXR{alpha}-dAF-2 (middle panel). YT-32 and T09013 [GenBank] 17 also induced the interaction of GST-SRC-1 and 35S-labeled LXR{beta} (lower panel).

 

Structure-function Relationship of YT-32 on LXRs—YT-32 is a sterol compound with a saturated cholesterol structure and the same side chain as ergosterol and brassicasterol (see Fig. 1 and Fig. 4A). YT-33 differs from YT-32 only in the absence of the 1{alpha}-hydroxyl group. Interestingly, whereas YT-32 is a potent ligand for LXR{alpha}, YT-33 completely lacks agonist activity, indicating that the presence of 1{alpha}-hydroxyl group is necessary for LXR{alpha} activation by YT-32 (Fig. 1A). To further examine the structure-function relationship between YT-32 and LXR{alpha}, we synthesized several YT-32 derivatives containing the 1{alpha}-hydroxyl group (Fig. 4A). YT-32 is a 22-ergosten with two hydroxyl groups at 1{alpha} and 3{beta} positions. Although YT-56 and YT-57 have the same hydroxyl groups and side chain configuration as YT-32, they are 5,22-dien and 5,7,22-trien, respectively. YT-59 has a saturated cholesterol ring structure like YT-32 but also has a saturated bond at C22. We compared dose-response curves of these compounds on full-length hLXR{alpha} (Fig. 4B). Among these compounds, YT-32 was the most potent LXR{alpha} activator (effective concentration for 50% maximal activation, EC50 = 0.41 µM), followed in rank order by YT-59 (EC50 = 1.3 µM) and YT-56 (EC50 = 15 µM). YT-57 had no activity on LXR{alpha}. Interestingly, YT-32 and YT-59 were able to activate LXR{alpha} more effectively than the natural oxysterol, 24(S),25-epoxycholesterol (EC50 = 0.81 µM). The data indicate that saturated cholesterol structure is important for LXR{alpha} activation, because activity decreases as saturation decreases (YT-32 > YT-56 > YT-57). Comparing YT-32 with YT-59, saturation at C22 slightly impairs LXR{alpha} activation. We next compared the effects of YT-32 and its related compounds on LXR{beta} (Fig. 4C). YT-32 induced activation of LXR{beta} similarly to 24(S),25-epoxycholesterol (EC50 = 1.1 µM for YT-32, 1.1 µM for 24(S),25-epoxycholesterol). YT-59 activated LXR{beta} less potently than YT-32 and 22(R)-hydroxycholesterol (EC50 = 8.8 µM for YT-59, 3.2 µM for 22(R)-hydroxycholesterol). YT-56 and YT-33 were not effective LXR{beta} agonists. Taken together, these data indicate that the 1{alpha}-hydroxyl group and saturated ring structure are important for LXR{alpha} and LXR{beta} activation.



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 4.
Structure-activity relationship of YT-32-derived LXR{alpha} agonists. A, structures of YT-32, its derivatives (YT-33, YT-56, YT-57, and YT-59), brassicasterol, ergosterol, 22(R)-hydroxycholesterol, and 24(S),25-epoxycholsterol. B, concentration-dependent activation of LXR{alpha} by YT-32 and its derivatives. Cells were cotransfected with CMX-hLXR{alpha} and rCYP7A-DR-4x3-tk-LUC and treated with several concentrations of YT-32 and the indicated compounds. C, concentration-dependent activation of LXR{beta} by YT-32 and its derivatives. Cells were cotransfected with CMX-mLXR{beta} and rCYP7A-DR-4x3-tk-LUC and treated with test compounds.

 

YT-32 Induces Intestinal ABC Transporter Genes—To investigate the in vivo effects of YT-32, we administered YT-32 orally to mice and examined the mRNA expression of target genes including ABC transporters in intestine and liver. YT-32 and T09013 [GenBank] 17 induced the expression of ABCA1, ABCG5, and ABCG8 in the intestine (Fig. 5A). The level of LXR{alpha} and LXR{beta} expression in the intestine were not changed by treatment with these compounds. As reported previously (8, 9), T09013 [GenBank] 17 induced the expression of ABCG5, ABCG8, SREBP-1c, and FAS but did not significantly induce that of ABCA1 in the liver. In contrast to the effects in intestine, YT-32 did not effectively increase the liver mRNA levels of LXR target genes (Fig. 5B). Expression of the LXR{alpha} and LXR{beta} genes in the liver was not changed after treatment with YT-32 or T09013 [GenBank] 17 (data not shown). YT-33, which lacks the 1{alpha}-hydroxyl group present in YT-32 and does not activate LXRs (see Figs. 1 and 4), did not change the expression of ABCA1, ABCG5, ABCG8, LXR{alpha}, or LXR{beta} in the intestine (Fig. 5C). Therefore, treatment with YT-32 induced the expression of intestinal ABC transporters but had slight or no observable effect on the expression of liver lipogenic genes.



View larger version (27K):
[in this window]
[in a new window]
  		FIG. 5.
LXR target gene expression in intestine and liver of mice treated with YT-32. Mice (n = 3) were orally administrated with 50 or 250 mg/kg of YT-32, 10 mg/kg of T09013 [GenBank] 17, or 250 mg/kg of YT-33. Twelve h after administration, total RNA was extracted from liver and intestinal mucosa. A, quantitative real-time PCR from intestinal RNA for ABCA1, ABCG5, ABCG8, LXR{alpha}, and LXR{beta} after treatment with YT-32 or T09013 [GenBank] 17. YT-32 and T09013 [GenBank] 17 significantly induced the intestinal expression of ABCA1, ABCG5, and ABCG8. B, quantitative real-time PCR from liver RNA for ABCA1, ABCG5, ABCG8, SREBP-1c, and FAS after treatment with YT-32 or T09013 [GenBank] 17. Although T09013 [GenBank] 17 induced the expression of SREBP-1c, as well as ABCG5 and ABCG8, YT-32 was not effective in inducing these genes in the liver. C, quantitative real-time PCR from intestinal RNA for ABCA1, ABCG5, ABCG8, LXR{alpha}, and LXR{beta} after treatment with YT-33. The values represent means ± S.D. *, p < 0.05 compared with the vehicle control.

 

YT-32 Inhibits Intestinal Cholesterol Absorption without Inducing Hypertriglycemia—The effects of YT-32 on intestinal cholesterol absorption and plasma triglyceride levels were examined. Mice were treated with YT-32, T09013 [GenBank] 17, or YT-33 for 12 h, and isotope-labeled cholesterol was administrated via gavage. As reported previously (33), plasma radioactivity increased gradually. Pretreatment with T09013 [GenBank] 17 and YT-32 decreased cholesterol absorption by 14 and 19%, respectively, 12 h after cholesterol administration, whereas YT-33 pretreatment did not change cholesterol absorption (Fig. 6A). The data strongly suggest that the cholesterol absorption-decreasing effect of YT-32 is mediated through LXRs. Treatment of mice with T09013 [GenBank] 17 increased plasma triglyceride as reported previously (Fig. 6B) (9). At a dose sufficient to effectively induce expression of ABCG5 and ABCG8 and inhibit intestinal cholesterol absorption, YT-32 did not alter plasma triglyceride levels (Fig. 6B). Treatment with YT-33 did not affect plasma triglycerides. Taken together, the LXR agonist YT-32 inhibited cholesterol absorption without inducing hypertriglycemia.



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 6.
YT-32 inhibits cholesterol absorption in the intestinal tract but does not increase plasma triglyceride. A, effects YT-32, T09013 [GenBank] 17, and YT-33 on cholesterol absorption. Mice (n = 4) were orally administrated with vehicle control, 250 mg/kg of YT-32, 10 mg/kg of T09013 [GenBank] 17, or 250 mg/kg of YT-33 and examined for cholesterol absorption. Mice were given isotope-labeled cholesterol 12 h after treatment with YT-32, T09013 [GenBank] 17, or YT-33. Blood was drawn from retroorbital sinus using microcapillary tubes 4, 8, and 12 h after administration of isotope-labeled cholesterol, and plasma radioactivity was measured. B, effects of YT-32, T09013 [GenBank] 17, and YT-33 on plasma triglyceride levels. Mice (n = 3) were orally administrated with 250 mg/kg of YT-32, 10 mg/kg of T09013 [GenBank] 17, or 250 mg/kg of YT-33, and blood was drawn for plasma triglyceride measurement 12 h after treatment. T09013 [GenBank] 17 induced hypertriglycemia, but YT-32 and YT-33 did not. The values represent means ± S.E. *, p < 0.05 compared with the vehicle control.

 


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
LXRs were originally identified as orphan members of the nuclear receptor superfamily and were later found to be receptors for endogenous oxysterols such as 22(R)-hydroxycholesterol and 24(S),25-epoxycholesterol (29, 31). The distribution of these natural ligands is tissue-specific. 24(S),25-Epoxycholesterol is formed in the liver via a shunt in the cholesterol biosynthetic pathway, whereas 22(R)-hydroxycholesterol is a transient intermediate in steroid hormone synthesis in the adrenal cortex. The limited systemic distribution of these oxysterols suggests the presence of other physiological LXR ligands. The finding that cholesterol-treated macrophages express the LXR-responsive ABCA1 and ABCG1 genes and utilize the enzyme CYP27 to produce 27-hydroxycholesterol and cholestenoic acid suggests that 27-hydroxycholesterol may serve as an endogenous ligand for LXRs (34). Cholestenoic acid was also reported to be an LXR{alpha} agonist (35). Cholesterol feeding increased the intestinal expression of ABCG5 and ABCG8 in wild-type mice but not in LXR{alpha}/{beta} null mice (8). Treatment with cholesterol or sitostanol increased the expression of the ABCA1 gene in intestinal cells (19). These findings suggest that LXRs are activated by metabolites of cholesterol and phytosterols in the intestine. However, the metabolic conversion of dietary sterols, such as cholesterol and phytosterols, has not been elucidated. In the present work, we show that an ergosterol derivative is a potent agonist for LXRs and induces the expression of ABC transporters in the mouse intestine. Our findings strongly suggest that the cholesterol-lowering effect of phytosterols is at least partly because of conversion of these compounds to LXR agonists, which activate the expression of sterol efflux transporters such as ABCG5 and ABCG8.

Several synthetic LXR agonists have been shown to modulate LXR regulation of cholesterol metabolism (9, 36, 37). Unfortunately, potent LXR agonists cause undesirable increases in liver and plasma triglyceride levels, because of the activation of LXR-responsive genes in the liver (SREBP-1c, FAS, and angiopoietin-like protein 3), in addition to their beneficial effects on cholesterol metabolism (10–13). SREBP-1c activates transcription of the major genes involved in fatty acid synthesis (acetyl CoA carboxylase, FAS, stearyl CoA desaturase-1, and glycerol-3-phosphate acyltransferase), and SREBP-1c transgenic mice show markedly increased liver triglycerides (38). Therefore, the development of selective modulators that act specifically on cholesterol metabolism without adverse lipogenic effects is required to realize the therapeutic potential of LXR pharmacophores.

We found that YT-32, a derivative of ergosterol or brassicasterol, activated LXR{alpha} more effectively than the known oxysterol agonists 24(S),25-epoxycholesterol and 22(R)-hydroxycholesterol and that it induced the expression of ABC transporter genes in the intestine. Interestingly, the induction of LXR-regulated genes in the liver was only modest or not observed. This selective action of YT-32 may be because of its sterol-based structure. YT-32 acts as a potent LXR agonist and induces the sterol exporting ABC transporters such as ABCA1, ABCG5, and ABCG8. ABCG5 and ABCG8 are expressed exclusively in liver and small intestine and are localized to the apical (canalicular) membrane of cells (39). Overexpression of these genes results in an ~50% reduction in absorption of dietary cholesterol and a dramatic increase in the biliary secretion of sterols (17). On the other hand, disruption of Abcg5 and Abcg8 in mice causes increased absorption of dietary phytosterols and a decrease in biliary cholesterol concentration (18). Therefore, ABCG5 and ABCG8 play an important role in biliary cholesterol secretion and the regulation of intestinal cholesterol absorption. Repa et al. (7) reported that ABCA1 expression was increased in the intestines of mice treated with a synthetic LXR agonist and suggested that ABCA1 catalyzed efflux causes the associated decrease in cholesterol absorption. However, the role of ABCA1 in intestinal cholesterol absorption remains to be clarified (2). ABCA1 was dominantly expressed on the basolateral surface of intestinal cells (40), and Plosch et al. (41) reported that the effect of the LXR agonist on fecal sterol loss was observed in Abca1 null mice, as well as wild-type mice. Recently (42), ABCG5 and ABCG8 were demonstrated to mediate the LXR agonist-mediated reduction of cholesterol absorption. YT-32 may reduce the intestinal absorption of dietary sterols, including cholesterol and phytosterols, by inducing the expression ABCG5 and ABCG8, which might excrete the compound from the basolateral membranes of the mucosal cells. Some fraction of YT-32 may be incorporated in the blood circulation where it could be available to stimulate the reverse cholesterol transport on atherosclerotic lesions. Alternatively, YT-32 may be secreted into the bile by ABCG5 and ABCG8 before it would be able to induce liver lipogenic genes. In contrast to YT-32, synthetic nonsteroidal agonists such as T09013 [GenBank] 17 do not seem to be substrates of the ABC transporters and cause increased serum and liver triglyceride levels by inducing lipogenic genes in the liver (9). Another possibility is that tissue selectivity of YT-32 is mediated by another mechanism as is the case for selective estrogen receptor modulators. The differential cofactor recruitment shown in Fig. 2D may contribute to tissue-specific agonist activity. Further analysis is required to elucidate the mechanism of tissue-specific LXR activation by YT-32. Therefore, our data suggest that LXR agonists based on the structure of natural sterols should be useful to agents in therapeutically modulating cholesterol metabolism.


   FOOTNOTES
 
* This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan, Suzuken Memorial Foundation, and Kampou Science Foundation (to M. Makishima) and by the 21st Century Center of Excellence (COE) Program from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to M. Matsuda). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Present address: Pharmacology Research Laboratories II, Pharmaceutical Research Division, Takeda Chemical Industries, 2-17-85 Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan. Back

** {ddagger}{ddagger} ** To whom correspondence may be addressed: Graduate School of Frontier Biosciences, Osaka University, 2-2 Yamadaoka, H2, Suita, Osaka 565-0871, Japan. Tel.: 81-6-6879-3272; Fax: 81-6-6879-3279; E-mail: ichi{at}fbs.osaka-u.ac.jp. {ddagger}{ddagger} To whom correspondence may be addressed: Graduate School of Frontier Biosciences, Osaka University, 2-2 Yamadaoka, H2, Suita, Osaka 565-0871, Japan. Tel.: 81-6-6879-3272; Fax: 81-6-6879-3279; E-mail: maxima{at}fbs.osaka-u.ac.jp.

1 The abbreviations used are: LXR, liver X receptor; ABC, ATP-binding cassette; FAS, fatty acid synthase; SREBP-1c, sterol regulatory element-binding protein-1c; RXR, retinoid X receptor; SRC-1, steroid receptor coactivator-1; GST, glutathione S-transferase; AF-2, activation function-2; EC50, effective concentration for 50% maximal activation; h, human; m, murine. Back

2 Y. Tachibana, unpublished data. Back


   ACKNOWLEDGMENTS
 
We thank K. Morita, R. Adachi, and H. Nakano for assistance in preparing plasmids, S. Furukawa for assistance in animal experiments, members of the Shimomura and Makishima laboratories for helpful comments, and Dr. David J. Mangelsdorf of Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX for providing plasmids and helpful comments.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Tabas, I. (2002) J. Clin. Invest. 110, 583-590[CrossRef][Medline] [Order article via Infotrieve]
  2. Lu, K., Lee, M. H., and Patel, S. B. (2001) Trends Endocrinol. Metab. 12, 314-320[CrossRef][Medline] [Order article via Infotrieve]
  3. Repa, J. J., and Mangelsdorf, D. J. (2002) Nat. Med. 8, 1243-1248[CrossRef][Medline] [Order article via Infotrieve]
  4. Lu, T. T., Repa, J. J., and Mangelsdorf, D. J. (2001) J. Biol. Chem. 276, 37735-37738[Free Full Text]
  5. Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., Tran, J., Tippin, T. K., Wang, X., Lusis, A. J., Hsueh, W. A., Law, R. E., Collins, J. L., Willson, T. M., and Tontonoz, P. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7604-7609[Abstract/Free Full Text]
  6. Tangirala, R. K., Bischoff, E. D., Joseph, S. B., Wagner, B. L., Walczak, R., Laffitte, B. A., Daige, C. L., Thomas, D., Heyman, R. A., Mangelsdorf, D. J., Wang, X., Lusis, A. J., Tontonoz, P., and Schulman, I. G. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 11896-11901[Abstract/Free Full Text]
  7. Repa, J. J., Turley, S. D., Lobaccaro, J. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., and Mangelsdorf, D. J. (2000) Science 289, 1524-1529[Abstract/Free Full Text]
  8. Repa, J. J., Berge, K. E., Pomajzl, C., Richardson, J. A., Hobbs, H., and Mangelsdorf, D. J. (2002) J. Biol. Chem. 277, 18793-18800[Abstract/Free Full Text]
  9. Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., Lustig, K. D., and Shan, B. (2000) Genes Dev. 14, 2831-2838[Abstract/Free Full Text]
  10. Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J. M., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., and Mangelsdorf, D. J. (2000) Genes Dev. 14, 2819-2830[Abstract/Free Full Text]
  11. Joseph, S. B., Laffitte, B. A., Patel, P. H., Watson, M. A., Matsukuma, K. E., Walczak, R., Collins, J. L., Osborne, T. F., and Tontonoz, P. (2002) J. Biol. Chem. 277, 11019-11025[Abstract/Free Full Text]
  12. Kaplan, R., Zhang, T., Hernandez, M., Gan, F. X., Wright, S. D., Waters, M. G., and Cai, T.-Q. (2003) J. Lipid Res. 44, 136-143[Abstract/Free Full Text]
  13. Inaba, T., Matsuda, M., Shimamura, M., Takei, N., Terasaka, N., Ando, Y., Yasumo, H., Koishi, R., Makishima, M., and Shimomura, I. (2003) J. Biol. Chem., 278, 21344-21351[Abstract/Free Full Text]
  14. Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T., and Furukawa, H. (2002) J. Biol. Chem. 277, 33742-33748[Abstract/Free Full Text]
  15. Jones, P. J. (1999) Curr. Atheroscler. Rep. 1, 230-235[Medline] [Order article via Infotrieve]
  16. Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., and Hobbs, H. H. (2000) Science 290, 1771-1775[Abstract/Free Full Text]
  17. Yu, L., Li-Hawkins, J., Hammer, R. E., Berge, K. E., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2002) J. Clin. Invest. 110, 671-680[CrossRef][Medline] [Order article via Infotrieve]
  18. Yu, L., Hammer, R. E., Li-Hawkins, J., Von Bergmann, K., Lutjohann, D., Cohen, J. C., and Hobbs, H. H. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 16237-16242[Abstract/Free Full Text]
  19. Plat, J., and Mensink, R. P. (2002) FASEB J. 16, 1248-1253[Abstract/Free Full Text]
  20. Tachibana, Y., and Tsuji, M. (1993) in Studies in Natural Products Chemistry (Rahman, A. U., ed) Vol. 11, pp. 379-408, Elsevier Science Publishers B.V., Amsterdam
  21. Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., and Mangelsdorf, D. J. (1995) Genes Dev. 9, 1033-1045[Abstract/Free Full Text]
  22. Willy, P. J., and Mangelsdorf, D. J. (1997) Genes Dev. 11, 289-298[Abstract/Free Full Text]
  23. Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., Haussler, M. R., and Mangelsdorf, D. J. (2002) Science 296, 1313-1316[Abstract/Free Full Text]
  24. Heery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. (1997) Nature 387, 733-736[CrossRef][Medline] [Order article via Infotrieve]
  25. Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A., Lobaccaro, J. M., Hammer, R. E., and Mangelsdorf, D. J. (1998) Cell 93, 693-704[CrossRef][Medline] [Order article via Infotrieve]
  26. Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., and Mangelsdorf, D. J. (2000) Mol. Cell 6, 507-515[CrossRef][Medline] [Order article via Infotrieve]
  27. Nishizawa, H., Yamagata, K., Shimomura, I., Takahashi, M., Kuriyama, H., Kishida, K., Hotta, K., Nagaretani, H., Maeda, N., Matsuda, M., Kihara, S., Nakamura, T., Nishigori, H., Tomura, H., Moore, D. D., Takeda, J., Funahashi, T., and Matsuzawa, Y. (2002) J. Biol. Chem. 277, 1586-1592[Abstract/Free Full Text]
  28. Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., and Shan, B. (1999) Science 284, 1362-1365[Abstract/Free Full Text]
  29. Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J. L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., and Willson, T. M. (1997) J. Biol. Chem. 272, 3137-3140[Abstract/Free Full Text]
  30. Moore, L. B., Maglich, J. M., McKee, D. D., Wisely, B., Willson, T. M., Kliewer, S. A., Lambert, M. H., and Moore, J. T. (2002) Mol. Endocrinol. 16, 977-986[Abstract/Free Full Text]
  31. Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., and Mangelsdorf, D. J. (1996) Nature 383, 728-731[CrossRef][Medline] [Order article via Infotrieve]
  32. Glass, C. K., and Rosenfeld, M. G. (2000) Genes Dev. 14, 121-141[Free Full Text]
  33. Wang, D. Q.-H., and Carey, M. C. (2003) J. Lipid Res., 44, 1042-1059[Abstract/Free Full Text]
  34. Fu, X., Menke, J. G., Chen, Y., Zhou, G., MacNaul, K. L., Wright, S. D., Sparrow, C. P., and Lund, E. G. (2001) J. Biol. Chem. 276, 38378-38387[Abstract/Free Full Text]
  35. Song, C., and Liao, S. (2000) Endocrinology 141, 4180-4184[Abstract/Free Full Text]
  36. Collins, J. L., Fivush, A. M., Watson, M. A., Galardi, C. M., Lewis, M. C., Moore, L. B., Parks, D. J., Wilson, J. G., Tippin, T. K., Binz, J. G., Plunket, K. D., Morgan, D. G., Beaudet, E. J., Whitney, K. D., Kliewer, S. A., and Willson, T. M. (2002) J. Med. Chem. 45, 1963-1966[CrossRef][Medline] [Order article via Infotrieve]
  37. Sparrow, C. P., Baffic, J., Lam, M.-H., Lund, E. G., Adams, A. D., Fu, X., Hayes, N., Jones, A. B., Macnaul, K. L., Ondeyka, J., Singh, S., Wang, J., Zhou, G., Moller, D. E., Wright, S. D., and Menke, J. G. (2002) J. Biol. Chem. 277, 10021-10027[Abstract/Free Full Text]
  38. Shimomura, I., Shimano, H., Korn, B. S., Bashmakov, Y., and Horton, J. D. (1998) J. Biol. Chem. 273, 35299-35306[Abstract/Free Full Text]
  39. Graf, G. A., Li, W.-P., Gerard, R. D., Gelissen, I., White, A., Cohen, J. C., and Hobbs, H. H. (2002) J. Clin. Invest. 110, 659-669[CrossRef][Medline] [Order article via Infotrieve]
  40. Ohama, T., Hirano, K., Zhang, Z., Aoki, R., Tsujii, K., Nakagawa-Toyama, Y., Tsukamoto, K., Ikegami, C., Matsuyama, A., Ishigami, M., Sakai, N., Hiraoka, H., Ueda, K., Yamashita, S., and Matsuzawa, Y. (2002) Biochem. Biophys. Res. Commun. 296, 625-630[CrossRef][Medline] [Order article via Infotrieve]
  41. Plosch, T., Kok, T., Bloks, V. W., Smit, M. J., Havinga, R., Chimini, G., Groen, A. K., and Kuipers, F. (2002) J. Biol. Chem. 277, 33870-33877[Abstract/Free Full Text]
  42. Yu, L., York, J., von Bergmann, K., Lutjohann, D., Cohen, J. C., and Hobbs, H. H. (2003) J. Biol. Chem. 278, 15565-15570[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J EndocrinolHome page
K. Segawa, M. Matsuda, A. Fukuhara, K. Morita, Y. Okuno, R. Komuro, and I. Shimomura
Identification of a novel distal enhancer in human adiponectin gene
J. Endocrinol., January 1, 2009; 200(1): 107 - 116.
[Abstract] [Full Text] [PDF]

Home page
 GENES CELLSHome page
M. Noshiro, E. Usui, T. Kawamoto, F. Sato, A. Nakashima, T. Ueshima, K. Honda, K. Fujimoto, S. Honma, K.-i. Honma, et al.
Liver X receptors (LXR{alpha} and LXR{beta}) are potent regulators for hepatic Dec1 expression
Genes Cells, January 1, 2009; 14(1): 29 - 40.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Hozoji, Y. Munehira, Y. Ikeda, M. Makishima, M. Matsuo, N. Kioka, and K. Ueda
Direct Interaction of Nuclear Liver X Receptor-{beta} with ABCA1 Modulates Cholesterol Efflux
J. Biol. Chem., October 31, 2008; 283(44): 30057 - 30063.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Hoon Lee, H. Gong, S. Khadem, Y. Lu, X. Gao, S. Li, J. Zhang, and W. Xie
Androgen Deprivation by Activating the Liver X Receptor
Endocrinology, August 1, 2008; 149(8): 3778 - 3788.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Callaghan, E. Crowley, S. Potter, and I. D. Kerr
P-glycoprotein: So Many Ways to Turn It On
J. Clin. Pharmacol., March 1, 2008; 48(3): 365 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H.-J. Kim, X. Fan, C. Gabbi, K. Yakimchuk, P. Parini, M. Warner, and J.-A. Gustafsson
Liver X receptor {beta} (LXR{beta}): A link between {beta}-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia
PNAS, February 12, 2008; 105(6): 2094 - 2099.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Inaba, K. Yamamoto, N. Yoshimoto, M. Matsunawa, S. Uno, S. Yamada, and M. Makishima
Vitamin D3 Derivatives with Adamantane or Lactone Ring Side Chains are Cell Type-Selective Vitamin D Receptor Modulators
Mol. Pharmacol., May 1, 2007; 71(5): 1298 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. F. Oram and A. M. Vaughan
ATP-Binding Cassette Cholesterol Transporters and Cardiovascular Disease
Circ. Res., November 10, 2006; 99(10): 1031 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
T. Plosch, J. K. Kruit, V. W. Bloks, N. C. A. Huijkman, R. Havinga, G. S. M. J. E. Duchateau, Y. Lin, and F. Kuipers
Reduction of Cholesterol Absorption by Dietary Plant Sterols and Stanols in Mice Is Independent of the Abcg5/8 Transporter
J. Nutr., August 1, 2006; 136(8): 2135 - 2140.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
F. Briand, S. Serisier, M. Krempf, B. Siliart, T. Magot, K. Ouguerram, and P. Nguyen
Atorvastatin Increases Intestinal Cholesterol Absorption in Dogs
J. Nutr., July 1, 2006; 136(7): 2034S - 2036S.
[Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. Plat, J. A. Nichols, and R. P. Mensink
Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation
J. Lipid Res., November 1, 2005; 46(11): 2468 - 2476.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. I. Shulman and D. J. Mangelsdorf
Retinoid X Receptor Heterodimers in the Metabolic Syndrome
N. Engl. J. Med., August 11, 2005; 353(6): 604 - 615.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Fukuen, M. Iwaki, A. Yasui, M. Makishima, M. Matsuda, and I. Shimomura
Sulfonylurea Agents Exhibit Peroxisome Proliferator-activated Receptor {gamma} Agonistic Activity
J. Biol. Chem., June 24, 2005; 280(25): 23653 - 23659.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. Adachi, Y. Honma, H. Masuno, K. Kawana, I. Shimomura, S. Yamada, and M. Makishima
Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative
J. Lipid Res., January 1, 2005; 46(1): 46 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M. G Traber
The ABCs of vitamin E and {beta}-carotene absorption
Am. J. Clinical Nutrition, July 1, 2004; 80(1): 3 - 4.
[Full Text] [PDF]

Home page
 J. Nutr.Home page
H. Tomoyori, Y. Kawata, T. Higuchi, I. Ichi, H. Sato, M. Sato, I. Ikeda, and K. Imaizumi
Phytosterol Oxidation Products Are Absorbed in the Intestinal Lymphatics in Rats but Do Not Accelerate Atherosclerosis in Apolipoprotein E-Deficient Mice
J. Nutr., July 1, 2004; 134(7): 1690 - 1696.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
G. A. Graf, J. C. Cohen, and H. H. Hobbs
Missense Mutations in ABCG5 and ABCG8 Disrupt Heterodimerization and Trafficking
J. Biol. Chem., June 4, 2004; 279(23): 24881 - 24888.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
F. J. Field, E. Born, and S. N. Mathur
LXR/RXR ligand activation enhances basolateral efflux of {beta}-sitosterol in CaCo-2 cells
J. Lipid Res., May 1, 2004; 45(5): 905 - 913.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/38/36091    most recent
M304153200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaneko, E.
Right arrow Articles by Makishima, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaneko, E.
Right arrow Articles by Makishima, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement